---
slug: kpv
title: "KPV: Evidence, Stability, Dosing and the FDA Record"
kind: essay
status: published
hash: 5301083ba2c220a3e7434c79d2fbc6469ddd29438d59c587077be69a3d615982
created: 2026-06-29 08:23:19
updated: 2026-10-08T11:51:26.195Z
summary: "KPV is three amino acids in a row — lysine, proline, valine. It is the tail end of a hormone your own body makes, alpha-MSH, which calms inflammation, darkens skin, and pushes on the heart and blood vessels. Cut the tail off and you keep"
tags: ["peptide","kpv"]
above: []
below: []
adjacent: []
nested: []
---
# KPV: Evidence, Stability, Dosing and the FDA Record

*KPV is three amino acids in a row — lysine, proline, valine. It is the tail end of a hormone your own body makes, alpha-MSH, which calms inflammation, darkens skin, and pushes on the heart and blood vessels. Cut the tail off and you keep*

KPV is three amino acids in a row — lysine, proline, valine. It is the tail end of a hormone your own body makes, alpha-MSH, which calms inflammation, darkens skin, and pushes on the heart and blood vessels. Cut the tail off and you keep the calming and lose the other two. That separation is the whole reason anyone works on it.

The evidence state, before anything else on this page. Randomised trials of KPV in people: none. Uncontrolled studies in people: none either. KPV has never been given to a person in any published study, by any route, at any dose. Asking the ClinicalTrials.gov programming interface for it on 4 August 2026 returned a total count of zero, and FDA searched the same databases independently in May 2026 and recorded that it had found no exposure data for products containing KPV given by any route. So the number of people who have ever taken it under measurement is nought, and there is no established human dose, no measured blood level, and no side-effect rate from a study. What does exist is 35 papers. The controlled results in them come from cultured human gut, airway and skin cells, and from mice, rats and rabbits: colitis in mice, a scraped cornea in rabbits, chemotherapy mouth ulcers in rats, a diabetic skin wound in mice. Every controlled win is in a lining one cell thick. Nothing in any species has put KPV against a tendon, a ligament, a joint or a spinal disc. And the counted record of what happens to people who buy it is 35 first-hand reports gathered from public threads, which is a record of exposure and not a test of whether it works.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.

Here is what is actually known, in the order it should be read.

Thirty-five papers have KPV in the title or abstract. Every controlled result in all of them came out of a dish, a mouse, a rat or a rabbit. In May 2026 the FDA ran its own search across PubMed, Embase, ClinicalTrials.gov, DailyMed, Drugs@FDA, Micromedex, the European and Japanese pharmacopoeias and the outsourcing-facility reporting database, arrived at the same count, and in July proposed that KPV be kept off the list of substances a pharmacy is allowed to compound. The receptor everyone assumed it works through has been tested three times and it is not the one. Plain KPV swallowed did nothing in the cleanest experiment ever run on it. And the two forms sold under the same name and the same CAS number differ in how much will dissolve by a factor of seven, which is why some people's vials go cloudy and others' do not.

None of that means the compound is inert. It means the honest version of what it does is narrower and stranger than what is being sold, and the parts that are solid are worth knowing exactly.

```widget
{
  "type": "source",
  "id": "w_iydnxytw"
}
```

## What is inflamed, what keeps it inflamed, and what would have to calm down

The tissue at the centre of this compound's whole record is a lining: the single layer of cells covering the inside of your gut, the surface of your eye, your airway, your gums, the underside of your skin. Every controlled win KPV has is in one of those.

**What breaks down.** A lining cell is held to its neighbour by tight junctions. Inflammation loosens them. Once loose, gut contents leak into the wall, immune cells arrive, and the cells release IL-1β, IL-6 and TNF-α — the three signals that show up in every KPV paper. Those signals loosen the junctions further. It is a loop that keeps itself running.

**What makes it break down faster.** More of the same signals. The master switch that turns them on is a protein pair called NF-κB, which sits idle in the body of the cell until inflammation frees it, at which point it walks into the nucleus and switches on the genes for all three cytokines. Every cycle of that loop damages more lining.

**What builds it back.** Lining cells divide fast — the gut resurfaces itself roughly every five days. The layer will rebuild itself if the inflammation stops. That is unusual and it is the reason this class of compound gets attention: you do not need to add anything, you need to remove the thing preventing repair.

**What makes it build back faster, and how strong each link is.** KPV walks into the nucleus itself and physically blocks NF-κB's ride into the nucleus — shown in a human airway cell line with the binding site identified, strong for a dish. That drops IL-1β, IL-6 and TNF-α — shown in mouse gut, rat gum, rabbit eye, human skin cells, consistent across four tissues, strong. Lower cytokines let the lining reseal — shown in mice and rats by wound closure and colon length, moderate. The same happens in a person — never tested by anyone, in any published study, by any route.

That last line is a row in the table, not the story. What follows is everything above it.

## The tanning half was cut off and the calming half stayed

Alpha-MSH is thirteen residues — SYSMEHFRWGKPV. The last three are K, P and V. KPV as a free base is C16H30N4O4, molecular weight 342.43 g/mol, CAS 67727-97-3. The acetate salt adds an acetic acid molecule for 402.5 g/mol and carries the same CAS number in most references. Neither form has a UNII code, a United States Pharmacopeia monograph, a European Pharmacopoeia monograph or a Japanese Pharmacopoeia monograph.

Alpha-MSH itself was studied as an anti-inflammatory for decades and never became one, because it drives melanin production and nobody wanted to tan a colitis patient to treat their colon. Cutting the molecule down to its last three residues removed that problem: KPV keeps almost all of the anti-inflammatory capacity of the full hormone and produces no pigment change at all.

```widget
{
  "type": "source",
  "id": "w_iz1zla8v"
}
```

That is the design idea, stated by the people who proposed it, and it is the one claim about KPV that the literature and the regulator both accept without argument.

## The obvious receptor was checked three times and it is not the one

Alpha-MSH works by docking onto melanocortin receptors, MC1 through MC5. The obvious guess was that its three-residue tail docks onto the same ones, more selectively. Three separate lines of evidence say it does not.

KPV cannot push radiolabelled alpha-MSH off rat brain tissue, off mouse melanoma cells, or off mouse immune cells carrying MC1R. Unlike alpha-MSH, it raises no cyclic AMP in those cells — meaning the docking signal never fires. Drug-blocking and gene-knockout approaches both failed to pin KPV's anti-inflammatory and wound-healing effects on MC2, MC3 or MC4.

```widget
{
  "type": "source",
  "id": "w_4lw9q2jv"
}
```

Human skin cells read the same. Neither alpha-MSH nor KPV produced any rise in cyclic AMP in HaCaT cells or in ordinary human skin cells. What did move was calcium inside the cell, across concentrations from 10⁻¹⁵ to 10⁻⁷ M.

```widget
{
  "type": "source",
  "id": "w_udmw8780"
}
```

The structural argument is blunter. KPV does not contain the sequence a molecule needs in order to bind any known melanocortin receptor at all — and it keeps the activity anyway. What it uses instead is not known.

```widget
{
  "type": "source",
  "id": "w_wo06gy2y"
}
```

So two things are settled. The anti-inflammatory effect is real in cells and animals. It is not a melanocortin receptor effect. What is open is what it is instead — and note the shape of that: this is a negative answer to a specific question, not an unexplored area. People were looking, and they found out it was not that.

## It stops the inflammation switch from reaching the nucleus

The best-worked-out candidate is physical interference. KPV gets in the way of the ride NF-κB takes into the nucleus.

In an immortalised human airway lining cell line, KPV cut NF-κB reporter activity, matrix metalloproteinase-9 activity, and release of IL-8 and eotaxin, and it did more of all of that at higher doses. The effect tracked with KPV's own movement into the nucleus, with stabilisation of IκBα, and with tagged p65RelA failing to get into the nucleus. Competition experiments put KPV at the importin-α3 binding site on p65RelA — importin-α3 is the shuttle protein that carries NF-κB in — probably jamming armadillo domains 7 and 8. A comparison peptide, γ-MSH, needed MC3R in the same experiment. KPV did not.

```widget
{
  "type": "source",
  "id": "w_0k5anu21"
}
```

Downstream, the pattern is the same everywhere it has been looked at: IL-1β, IL-6 and TNF-α fall. In immune cells stimulated with bacterial wall fragments, in colon tissue from mice with colitis, in rat gum tissue and in human skin cells stressed with air pollution particles, those three are what move.

```widget
{
  "type": "source",
  "id": "w_tfx8zspw"
}
```

Calming inflammation in a dish is not the same as calming inflammation in a person, and the gap between those two is where every unanswered question about KPV lives.

## A door in the gut wall that opens wider the sicker the gut gets

PepT1 is a transporter built to pull two- and three-amino-acid fragments out of the gut and into the cell. It sits in the small intestine normally, is barely present in a healthy colon, and appears in large amounts in the colon lining during inflammatory bowel disease. KPV is a tripeptide. It fits through.

Radiolabelled KPV is carried by human PepT1 with a half-saturation point of roughly 160 µM in Caco2-BBE gut lining cells and roughly 700 µM in Jurkat immune cells, and unlabelled KPV competes with glycyl-sarcosine, the standard test substrate for that transporter. Once inside, concentrations in the billionths of a molar were enough to shut down NF-κB and MAP kinase signalling.

```widget
{
  "type": "source",
  "id": "w_ky34gd73"
}
```

The transporter is not incidental to the story — it is the story. In mice given azoxymethane plus dextran sodium sulfate to trigger colitis and then colon cancer, KPV prevented the cancer in normal animals and did nothing whatsoever in animals bred without PepT1. Take the door away and the drug stops working.

```widget
{
  "type": "source",
  "id": "w_txhlsxnq"
}
```

This is why swallowing and rectal use get discussed at all for a peptide you would otherwise assume needs a needle. It also makes a specific, testable prediction: the sicker the colon, the more doors, and therefore the more gets in. That prediction has been confirmed in mice. It has never been checked in a person.

## Every controlled result comes from a dish, a mouse, a rat or a rabbit

The three tables below are the complete usable evidence base, split by what kind of system produced each result. Doses are exactly as the papers report them.

**In a dish**

| Study | Model | Route | Dose | What happened |
|---|---|---|---|---|
| Dalmasso 2008 (PMID 18061177) | Caco2-BBE, HT29-Cl.19A, Jurkat T cells | in the culture fluid | billionths of a molar; half-saturation 160 µM in gut cells, 700 µM in Jurkat | NF-κB and MAP kinase signalling shut down; uptake through PepT1 confirmed with tritium-labelled KPV |
| Land 2012 (PMID 22837805) | 16HBE14o- human airway lining | in the culture fluid | more effect at higher dose | IL-8, eotaxin, MMP-9 down; p65RelA blocked from the nucleus at the importin-α3 site |
| Cutuli 2000 (PMID 10670585) | *Staphylococcus aureus*, *Candida albicans* | in the culture fluid | trillionths of a molar and above | Colonies failed to form; yeast survival and germ-tube formation fell; white cells killed both organisms better rather than worse |
| Grieco 2005 (PMID 15946192) | Azole-resistant *Candida* species | in the culture fluid | not stated | The [Ac-CKPV]₂ double version kills the yeast; NMR shows a stretched backbone with a β-turn |
| Hedley 2004 (PMID 15102092) | HaCaT and ordinary human skin cells | in the culture fluid | 10⁻¹⁵ to 10⁻⁷ M | No cyclic AMP rise; calcium inside the cell rose |
| Pawar 2017 (PMID 28343991) | Sliced human cadaver skin | on the surface | left on, against microneedles, against a small electric current | Left on its own, nothing crossed above the 0.01 µg/mL detection limit; microneedles gave 4.4 µg/cm²/h; adding current multiplied that by 35 |
| Tissue Cell 2025 (PMID 40073467) | HaCaT skin cells and a 3D skin model, air pollution insult | in the culture fluid | 50 µg/mL | Cells survived; IL-1β, reactive oxygen and caspase-1 activation all fell |
| Cytotechnology 2026 (PMID 42064835) | HepG2 liver cells, fat-loaded | in the culture fluid | 100 µg/mL | Fat accumulation and fatty-acid synthase suppressed through PPARγ, with no cell death |

**In animals**

| Study | Model and species | Route | Dose | What happened |
|---|---|---|---|---|
| Lipton 1984 (PMID 6333677) | Rabbit fever from white-cell pyrogen | into the brain and into the body | 0.5–2.0 mg into the brain; 2–200 mg into the body | Fever fell by both routes; weaker than whole alpha-MSH |
| Hiltz & Lipton 1989 (PMID 2550304) | Mouse ear swelling, picryl chloride | into the body | graded doses | Swelling fell, more at higher doses, compared against a large steroid dose |
| Bonfiglio 2006 (PMID 16965771) | Rabbit corneal scrape | eye drops | 1, 5 or 10 mg/mL, 30 µL, two drops four times a day for 4 days | 8 of 8 corneas fully resurfaced by 60 hours; the effect disappeared when nitric oxide production was blocked |
| Dalmasso 2008 (PMID 18061177) | Mouse DSS and TNBS colitis | in the drinking water | 100 µM | Weight loss, myeloperoxidase and inflammatory cytokine messenger RNA all reduced |
| Kannengiesser 2008 (PMID 18092346) | Mouse DSS colitis and CD45RB-high transfer colitis | into the body | not stated in abstract | Earlier recovery, weight regained, less immune cell infiltrate and less myeloperoxidase; in mice with a broken MC1R, every treated animal survived |
| Laroui 2010 (PMID 19909746) | Mouse DSS colitis | swallowed, 400 nm particles in an alginate–chitosan gel | 12,000 times lower than free solution | The same protection at one twelve-thousandth of the concentration |
| Viennois 2016 (PMID 27458604) | AOM/DSS colitis-driven cancer, normal against PepT1-knockout mice | swallowed | not stated in abstract | Cancer prevented in normal mice; no effect at all without PepT1 |
| Xiao 2017 (PMID 28143741) | Mouse ulcerative colitis | swallowed, hyaluronic-acid particles in a chitosan/alginate gel | ~272 nm particles | Lining healed faster and TNF-α fell; better than plain KPV particles |
| ACS Biomater Sci Eng 2021 (PMID 34547895) | Rat TNBS ulcerative colitis | rectal, thiolated γ-polyglutamic acid gel | 4% polymer gel | Disease activity, colon shortening, myeloperoxidase, TNF-α and IL-6 all reduced; plain rectal KPV fell apart too fast to work |
| Biomater Sci 2021 (PMID 34846053) | Rat chemotherapy mouth ulcers, MRSA-infected | sticky gel that sets at body heat | 2% EGCG carrier | Gum ulcers repaired, IL-1β and TNF-α down, IL-10 up, and it killed *S. aureus* |
| Int J Biol Macromol 2022 (PMID 36240893) | Diabetic mouse full-thickness wound | layered film dressing | KPV released over 3 days, EGF released in response to glucose | Faster closure, through less inflammation, new blood vessel growth and collagen laid down |
| Adv Healthc Mater 2024 (PMID 39252648) | Mouse blood vessel calcification | KPV–rapamycin particles with no carrier | self-assembling | Calcification blocked; inflammation down and cell self-cleaning switched on |
| Sci Adv 2026 (PMC12802832) | Mouse DSS colitis and acute lung injury | swallowed, self-uncaging prodrug | proKPV 0.5 and 2.5 mg/kg daily × 7 days | Weight, disease activity and colon length all protected — while **plain KPV at the matching 1 mg/kg peptide dose did nothing at all** |

**In people**

| Study | Model | Route | Dose | What happened |
|---|---|---|---|---|
| — | — | — | — | Nothing published. KPV has never been given to a person in a published study, by any route |

Asking the ClinicalTrials.gov programming interface for KPV peptide on 4 August 2026 returned `{"totalCount": 0}`.

```widget
{
  "type": "source",
  "id": "w_46rh3j3w"
}
```

FDA searched independently and found the same. The nomination that put KPV in front of the agency cited nine references: eight were animal studies of various alpha-MSH derivatives, and the ninth was a skin-permeation experiment on cadaver skin.

```widget
{
  "type": "source",
  "id": "w_4lw9q2jv"
}
```

## Plain KPV falls apart, which is why most of the research is about packaging

Read the animal table again and one thing is impossible to miss: hydrogels, nanoparticles, liposomes, film dressings, prodrugs, gels that set at body heat. That is not fashion. That is a whole field routing around a defect.

Put KPV under acid, alkali or hydrogen peroxide and the main thing you get back is lysine-proline-diketopiperazine. The lysine and proline ends curl round and bond to each other, the ring closes, and the peptide is gone.

```widget
{
  "type": "source",
  "id": "w_4hqievsz"
}
```

KPV solution given rectally was described flatly as "very unstable", which is why the rat colitis work needed a thiolated polymer gel just to hold it together for two hours at body temperature.

```widget
{
  "type": "source",
  "id": "w_6tepv8p6"
}
```

The 2026 prodrug paper is the cleanest measurement of what that costs. Plain KPV swallowed at 1 mg/kg did nothing in mouse colitis. The same peptide, chemically caged so it survives the stomach and uncages only where reactive oxygen marks inflamed tissue, worked at half that dose and reached 3.8 times the concentration in the colon.

```widget
{
  "type": "source",
  "id": "w_yd7rqb37"
}
```

Trying to toughen the molecule by chemistry rather than packaging has cost the activity outright. Sticking a sugar-alkyl group on the lysine produced versions that shrugged off protein-cutting enzymes and killed nothing under any condition tested — including the acetylated parent.

```widget
{
  "type": "source",
  "id": "w_ggr3cicc"
}
```

Two things follow, and both are practical.

Nothing in the animal record shows that plain, unpackaged KPV swallowed reaches inflamed tissue in a useful amount. One paper specifically shows it does not.

And the storage numbers in the regulatory file are the ones to work from: dry powder is reported good for up to three years at −20 °C, two years at 4 °C, and three months at 15 °C, while once it is in water it is reported at six months at −80 °C, one month at −2 °C and one week at 10 °C.

```widget
{
  "type": "source",
  "id": "w_4lw9q2jv"
}
```

## The two salts differ in how much will dissolve by a factor of seven

This is the detail most likely to leave you holding a cloudy vial and wondering whether you ruined it.

KPV free base dissolves in water only up to 0.70 mg/mL. KPV acetate is reported to dissolve at 5 mg/mL.

```widget
{
  "type": "source",
  "id": "w_4lw9q2jv"
}
```

Now do the arithmetic everyone does. A 10 mg vial with 2 mL of water in it is aiming for 5 mg/mL.

If the powder is the acetate salt, 5 mg/mL sits exactly on the reported ceiling — it will go in, with nothing to spare.

If the powder is the free base, 5 mg/mL is about seven times more than will dissolve. It physically cannot all go into solution. What you get is a suspension that looks nearly right, and the amount of actual peptide in each syringe depends on how recently you swirled it.

The part that makes this a real problem rather than a solvable one: the two forms share the same CAS number and are labelled inconsistently, so the container often does not tell you which one you have. FDA said exactly that, and called the naming conventions non-compliant with INN, IUPAC and USAN standards for that reason. If you want a fill that works either way, 0.70 mg/mL is the number that clears both — a 10 mg vial in 14 mL, which nobody does, or a smaller vial in more water.

## One mark on the syringe is fifty micrograms

A U-100 insulin syringe holds 1 mL across 100 marks. One mark is 0.01 mL. Everything else falls out of the concentration.

Start there:

- 10 mg powder ÷ 2 mL bacteriostatic water = **5 mg/mL = 5,000 mcg/mL**
- 1 mark = 0.01 mL × 5,000 mcg/mL = **50 mcg per mark**

| Marks on the barrel | Volume | Dose at 5 mg/mL | Dose at 2.5 mg/mL (10 mg in 4 mL) | Dose at 2 mg/mL (10 mg in 5 mL) |
|---|---|---|---|---|
| 2 | 0.02 mL | 100 mcg | 50 mcg | 40 mcg |
| 4 | 0.04 mL | 200 mcg | 100 mcg | 80 mcg |
| 5 | 0.05 mL | 250 mcg | 125 mcg | 100 mcg |
| 10 | 0.10 mL | 500 mcg | 250 mcg | 200 mcg |
| 20 | 0.20 mL | 1,000 mcg (1 mg) | 500 mcg | 400 mcg |
| 40 | 0.40 mL | 2,000 mcg (2 mg) | 1,000 mcg | 800 mcg |

Putting the same 10 mg into 4 mL instead of 2 mL halves every number in the column and doubles the volume you inject for a given dose. That is usually the point: small doses are easier to measure when each mark is worth less. It also drops you to 2.5 mg/mL, which is under the acetate ceiling with room to spare and still five times over the free base's, so it does not solve the salt problem.

The dose people actually take rests on a unit conversion, not a trial. Scaled from rodent studies by body surface area, a human-equivalent starting dose has been published at around 0.2 mg — four marks on a 5 mg/mL fill.

```widget
{
  "type": "source",
  "id": "s7"
}
```

That number carries the weight of an arithmetic conversion and nothing else. Nobody has measured how the body absorbs and clears KPV free base or KPV acetate, in any species. There is no measured half-life, no figure for how much reaches the blood, and no dose-response curve anywhere that would let a human dose be worked out rather than scaled from a mouse.

```widget
{
  "type": "source",
  "id": "w_4lw9q2jv"
}
```

## What people taking it report, counted: 28 helped, 4 worse, 3 both, of 35

Sixty first-hand posts about KPV are catalogued as sources on this page — fifty from Reddit, ten from X, all pulled on 29 June 2026. Twenty-five of them are guides, product write-ups, questions, or regulatory commentary with no outcome in them. That leaves **35 posts where a named person says what they took and what happened**.

Sorted by what they actually reported:

| What was reported | Posts | Share of the 35 |
|---|---|---|
| Something got better | 28 | 80% |
| Something got better *and* a bad reaction happened, or the route mattered | 3 | 9% |
| A bad effect was the whole report | 4 | 11% |
| Nothing at all happened | 0 | 0% |

Read that honestly in both directions. This is a curated set, pulled from threads people started because they had something to say, and the direction of that bias is upward — nobody posts "took a peptide, nothing occurred, no further questions." The zero in the bottom row is the tell. For DSIP, catalogued the same way on the same day, five of thirty-five reports said nothing happened. Here, none did. Either KPV does something noticeable to nearly everyone who takes it, or the silent non-responders are not in the sample. Both of those can be true at once.

What the set is genuinely good for is a dose survey and a side-effect list, and on those two it is consistent. On a 10 mg vial in 2 mL — 50 mcg per mark — the reported range runs from four marks to ten. **200 to 500 mcg a day under the skin is what people take.**

### The 28 who said something got better

Twelve days under the skin at 200 mcg, one 5 mg vial, for gut symptoms — labelled anecdotal:

```widget
{
  "type": "source",
  "id": "s17"
}
```

Forty days at 500 mcg a day, for mast cell symptoms:

```widget
{
  "type": "source",
  "id": "s20"
}
```

Same condition, a different person, putting a number on it:

```widget
{
  "type": "source",
  "id": "s24"
}
```

r/MCAS again, on fatigue and food tolerance:

```widget
{
  "type": "source",
  "id": "s23"
}
```

Roughly 300 mcg a night by injection, from r/MCAS — and, from the same thread, the swallowed form causing flares where the injected form did not:

```widget
{
  "type": "source",
  "id": "s47"
}
```

Skin is the second cluster. Eczema, four to five weeks in, with symptoms returning within two days of stopping:

```widget
{
  "type": "source",
  "id": "s60"
}
```

```widget
{
  "type": "source",
  "id": "s75"
}
```

```widget
{
  "type": "source",
  "id": "s58"
}
```

Hidradenitis, in a stack:

```widget
{
  "type": "source",
  "id": "s100"
}
```

Then the reports where the benefit is real but short. Two people independently describe roughly forty-eight hours of relief per injection and then a return to baseline:

```widget
{
  "type": "source",
  "id": "s61"
}
```

```widget
{
  "type": "source",
  "id": "s53"
}
```

And the outliers, which are worth keeping visible precisely because a single report proves nothing: a person whose supraventricular tachycardia episodes stopped for two months and came back two days after stopping the peptide:

```widget
{
  "type": "source",
  "id": "s83"
}
```

```widget
{
  "type": "source",
  "id": "s82"
}
```

```widget
{
  "type": "source",
  "id": "s62"
}
```

The rest of the 28 — histamine tolerance, general inflammation, skin, nail fungus, dandruff, food reactions, rheumatoid arthritis alongside prescribed drugs, sacroiliac pain in a stack, hair thickening in a blend, and several "keeps it in the stack year-round" posts:

```widget
{
  "type": "source",
  "id": "s22"
}
```

```widget
{
  "type": "source",
  "id": "s27"
}
```

```widget
{
  "type": "source",
  "id": "s32"
}
```

```widget
{
  "type": "source",
  "id": "s48"
}
```

```widget
{
  "type": "source",
  "id": "s63"
}
```

```widget
{
  "type": "source",
  "id": "s64"
}
```

```widget
{
  "type": "source",
  "id": "s74"
}
```

```widget
{
  "type": "source",
  "id": "s85"
}
```

```widget
{
  "type": "source",
  "id": "s89"
}
```

```widget
{
  "type": "source",
  "id": "s103"
}
```

### The 4 where a bad effect was the whole report

At the same doses. This matters — the negatives are not from people megadosing.

200 mcg, and the complaint is not physical at all:

```widget
{
  "type": "source",
  "id": "s25"
}
```

250 mcg a night, day four:

```widget
{
  "type": "source",
  "id": "s46"
}
```

An acute reaction within an hour of a small injected volume:

```widget
{
  "type": "source",
  "id": "s43"
}
```

Dizziness, broken sleep, headaches, brain fog and fatigue, from a long-covid gut thread:

```widget
{
  "type": "source",
  "id": "s19"
}
```

### The 3 who got both

Eight days of clear improvement, then red bumps out of nowhere:

```widget
{
  "type": "source",
  "id": "s54"
}
```

Gut repair, but only after months of climbing the dose slowly, with paradoxical reactions early:

```widget
{
  "type": "source",
  "id": "s21"
}
```

And the one that splits by route rather than by person — swallowed did nothing measurable, injected moved a blood marker a long way:

```widget
{
  "type": "source",
  "id": "s101"
}
```

### Two patterns worth naming out loud

The first is a frame, not a finding. Fatigue, apathy and flu-like malaise appear over and over at 200–500 mcg, and the standard community explanation is a die-off or healing flare. That explanation cannot be wrong, because there is no result it excludes — every bad reaction becomes evidence the compound is working. Treat it as what it is: an unfalsifiable story wrapped around an adverse effect.

The second is a real, testable claim, and it appears in enough reports to take seriously: people who started very low and climbed slowly report the paradoxical reactions going away. That is a dose-response observation, and it is the only actionable thing the whole self-report record produces.

```widget
{
  "type": "source",
  "id": "s21"
}
```

Duration is the other thing the reports agree on and the animal literature never measured. The effect is described as lasting days, not weeks — which fits a three-amino-acid peptide with no measured half-life and a known tendency to curl up into a diketopiperazine and stop existing.

```widget
{
  "type": "source",
  "id": "s53"
}
```

None of this substitutes for a trial. It does establish three facts you would otherwise learn by accident: the dose is 200–500 mcg under the skin, bad reactions at that dose are common enough to fill threads, and the swallowed and injected forms are not experienced as the same thing.

## Swallowed, injected, rubbed on, sprayed up the nose — what changes

All four are sold. The evidence behind each is not remotely equal.

**Swallowed** has the strongest mechanical case, because PepT1 is a real door, KPV is a real fit for it, and the door opens wider in inflamed bowel. Against that: the single experiment that pitted plain swallowed KPV against a packaged version found the plain version inert.

**Rectal** puts the peptide against the target tissue directly, and was shown to need a stabilising gel to survive long enough to do anything.

**Rubbed on** has an explicit measurement against it. Across human cadaver skin, KPV left on the surface crossed at a rate below the 0.01 µg/mL detection limit. It took microneedles punching through the outer layer to reach 4.4 µg/cm²/h, and a small electric current on top of that to multiply it further. Nothing crosses intact skin on its own in any amount you can measure.

```widget
{
  "type": "source",
  "id": "w_62ka3qz2"
}
```

FDA reached the same conclusion and pointed out that it cuts both ways: poor skin crossing limits how much reaches the bloodstream and therefore limits systemic toxicity, and it equally limits KPV's usefulness as a cream, because it may never reach the living skin layers under the dead outer one.

```widget
{
  "type": "source",
  "id": "w_4lw9q2jv"
}
```

**Sprayed up the nose** has no published measurement of any kind.

## It kills bacteria and yeast in a dish and has never been measured in a body

Alpha-MSH peptides including KPV stopped *Staphylococcus aureus* forming colonies and cut *Candida albicans* survival and germ-tube formation, down to concentrations in the trillionths of a molar. Unusually for an anti-inflammatory, they made white blood cells kill both organisms better rather than worse — most things that calm inflammation blunt that.

```widget
{
  "type": "source",
  "id": "w_8b4pdcfy"
}
```

The version taken furthest toward antifungal development is the double, [Ac-CKPV]₂, built by joining two KPV units through a cysteine-cysteine bridge. It works against *Candida* strains that azole drugs no longer touch.

```widget
{
  "type": "source",
  "id": "w_4rk4kjx2"
}
```

The MRSA result in the rat mouth-ulcer model is the closest thing to a confirmation in a living animal, and it needed a sticky gel holding the peptide against the wound for seven hours to get there.

```widget
{
  "type": "source",
  "id": "w_jcn0rn64"
}
```

## Where the evidence stops, and the swap that gets made

Two things in this file are solid enough to act on, and neither is a musculoskeletal finding.

The first is inflammation in a lining. Every controlled win KPV has is in one — bowel, cornea, airway, skin, gum. If your problem is a gut that is inflamed, that is the strongest part of this record and it is genuinely the strongest part.

The second is the pairing with BPC-157, which is what most gut protocols actually run.

![[bpc-kpv-gut-repair]]

Now the swap, because it is made constantly and it is worth being able to spot.

No study in any table above used a tendon, a ligament, a disc or a joint. There is no rat Achilles study. No ligament cut study. No cartilage study. The wound-healing results are all in linings — a scraped cornea, a diabetic skin wound, a mouth ulcer — and resealing a one-cell-thick lining is a different job from rebuilding collagen in a tendon. Lining cells divide every few days and re-cover a surface. Tendon rebuilds by laying down and remodelling collagen fibres over months, using different cells and a different signal set.

So the sentence "KPV helps tissue heal" is true and useless, and it is the sentence that does the work. Someone reads it and hears "KPV will help my rotator cuff." That is a cornea result laundered into a shoulder claim, and the laundering happens in the word *tissue*.

The honest version is four clauses long. KPV reduces inflammatory signalling in the linings of animals. It has never been given to a person in a published study. It has no measured human dose. And it is currently proposed for exclusion from legal compounding in the United States.

## FDA proposed in July 2026 that KPV stay off the compounding list

The regulatory position has two layers and they get conflated constantly.

The older layer: KPV sits on FDA's table of bulk drug substances that were nominated for compounding and then withdrawn by whoever nominated them, filed under substances that may present significant safety risks. The agency's entry says it "has not identified any human exposure data on drug products containing KPV administered via any route of administration" and "lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans."

```widget
{
  "type": "source",
  "id": "w_fquamfa9"
}
```

The newer layer matters more. The nomination was withdrawn, and FDA chose to take KPV to its advisory committee anyway. On 23 July 2026 the Pharmacy Compounding Advisory Committee heard KPV free base and KPV acetate alongside BPC-157, TB-500 and MOTS-c, with the uses under evaluation recorded as wound healing and inflammatory conditions.

```widget
{
  "type": "source",
  "id": "w_x3r14ud2"
}
```

FDA's position going in was not ambiguous: "FDA is proposing that KPV (free base) NOT be included on the 503A Bulks List" and "FDA is proposing that KPV acetate NOT be included on the 503A Bulks List."

```widget
{
  "type": "source",
  "id": "w_b5ztk84s"
}
```

The reasoning, dated 12 May 2026, weighed four criteria and found against on all four.

Neither form is well characterised: the naming is inconsistent, and no certificate of analysis, impurity profile, clumping test or microbiology data was supplied or found in the literature.

How much it has historically been compounded is unknown: outsourcing facilities reported compounding no KPV products at all between January 2017 and June 2025, while telehealth and compounding websites sell injectable, swallowed, topical and nasal-spray KPV for inflammatory conditions, wound healing, skin health, gut health, killing microbes, and protection against nerve damage and stroke.

There is no evidence it works, because there is no human data.

And there is no safety evidence in either direction.

```widget
{
  "type": "source",
  "id": "w_4lw9q2jv"
}
```

What that means in practice: getting onto the 503A Bulks List is what makes a substance lawfully compoundable when it has no monograph and is not part of an approved drug. FDA has proposed it not get on.

## Unknown is not the same as safe

FDA's Office of Surveillance and Epidemiology searched the FDA Adverse Event Reporting System and the medical literature for harms linked to KPV, through 3 December 2025. The reporting system returned nothing. The literature search found no cases. A separate search of the Human Foods Program adverse event system covering 1 January 2004 to 3 December 2025 also came back empty.

```widget
{
  "type": "source",
  "id": "w_4lw9q2jv"
}
```

An empty harm database for a substance nobody has published on giving to humans measures the literature, not the compound. Reporting to that system is voluntary, and compounders working under section 503A generally do not report to FDA at all. Meanwhile four of the thirty-five first-hand posts above describe a bad reaction, and none of those four is in any database.

No acute toxicity study exists. No repeat-dose toxicity study. No genotoxicity study. No developmental or reproductive toxicity study, of either form. FDA's stated worry is clumping and whether the immune system reacts to it, and neither can be assessed without the impurity and aggregate data the nomination never supplied.

The narrower operative fact: what circulates is research-grade powder from suppliers whose certificates of analysis FDA could not locate, and the agency's specific objection is that nobody can tell from the label whether a given vial holds the free base or the acetate — which, per the section above, decides whether your 10 mg in 2 mL is a solution or a suspension.

## Where every number above came from

**Primary literature, by PubMed identifier.** PMID 18061177 (PepT1 uptake, *Gastroenterology* 2008); PMID 18092346 (DSS and transfer colitis, *Inflammatory Bowel Diseases* 2008); PMID 27458604 (PepT1 knockout and colitis-driven cancer, 2016); PMID 22837805 (p65RelA blocked from the nucleus, 2012); PMID 21222263 and PMID 18612139 (the melanocortin-receptor-independence argument); PMID 15102092 (skin cell cyclic AMP and calcium); PMID 10670585 and PMID 15946192 (killing microbes, and the CKPV double); PMID 16965771 (rabbit cornea); PMID 2550304 and PMID 6333677 (the original mouse and rabbit work, 1989 and 1984); PMID 25298219 (the stability assay and the diketopiperazine breakdown product); PMID 28343991 (human cadaver skin); PMID 19909746, PMID 28143741, PMID 34547895, PMID 34846053, PMID 36240893, PMID 39252648 and PMC12802832 (the packaging literature); PMID 29953505 (sugar-alkyl versions, activity lost); PMID 40073467 and PMID 42064835 (recent skin and liver cell work).

**Trial registries.** ClinicalTrials.gov programming interface v2, query "KPV peptide", 4 August 2026: `{"totalCount": 0}`. No registered study of KPV in people exists.

```widget
{
  "type": "source",
  "id": "w_46rh3j3w"
}
```

**Regulatory record.** FDA's evaluation of KPV-related bulk drug substances dated 12 May 2026; the briefing document proposing exclusion from the 503A Bulks List; the Federal Register notice of 16 April 2026 announcing the meeting and the uses evaluated; and the standing FDA page listing KPV among bulk substances nominated but withdrawn.

```widget
{
  "type": "source",
  "id": "w_zjkqhidi"
}
```

**Chemistry.** PubChem CID 125672 for the free base; CAS 67727-97-3 for both forms; molecular weight 342.43 g/mol free base and 402.5 g/mol acetate; water solubility 0.70 mg/mL free base and 5 mg/mL acetate.

**Both sides on the record.** In favour, the researchers who characterised the molecule: Brzoska and colleagues concluded that keeping the anti-inflammatory effect while losing the pigment effect makes KPV "an alternative for antiinflammatory therapy", and that its physical properties and low expected production cost suit inflammatory skin and bowel disease. Böhm and Luger, cited in FDA's own nonclinical review, went further and called for clinical studies to find out whether KPV could heal skin wounds and ulcers — a call that, as of August 2026, nobody has answered. Against, the regulator, in its own words: "There is a lack of clinical and nonclinical safety information on the use of KPV (free base) and KPV acetate. FDA is particularly concerned about the lack of any human data on drug products containing these substances…"

```widget
{
  "type": "source",
  "id": "w_4lw9q2jv"
}
```

**The three hardest numbers in the file**, because everything else is softer than they are: nothing measurable crosses intact human skin, at a detection limit of 0.01 µg/mL; the PepT1 half-saturation point in gut lining is 160 µM; and the main breakdown product under stress is lysine-proline-diketopiperazine.

*KPV is not an approved drug in any country. Nothing here is a dosing or treatment recommendation.*

The sibling objects for this page, each one inspectable on its own terms:

![[bpc-157]]

![[tb-500]]

![[thymosin-alpha-1]]

![[ghk-cu]]

![[ara-290]]

## Facts

```json
{
  "converted_from": "markdown",
  "original_updated": "2026-08-04T20:48:18.853Z",
  "register": "essay",
  "category": null
}
```

## Sources

1. [PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation](https://pubmed.ncbi.nlm.nih.gov/18061177/) — “KPV acts via PepT1 expressed in immune and intestinal epithelial cells... Nanomolar concentrations of KPV inhibit the activation of NF-κB and MAP kinase inflammatory signaling pathways” (sha256 4378310bcb95ff3d)
2. [Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease](https://pubmed.ncbi.nlm.nih.gov/18092346/) — “The melanocortin-derived tripeptide KPV showed significant anti-inflammatory effects in 2 murine models of colitis” (sha256 77ed0699b17b2777)
3. [PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation](https://pubmed.ncbi.nlm.nih.gov/18061177/) — “oral administration of KPV reduces the incidence of DSS- and TNBS-induced colitis” (sha256 0505e2fdc01e958f)
4. [KPV: The Anti-Inflammatory Tripeptide for Gut and Skin](https://meto.co/blog/kpv-peptide-anti-inflammatory-gut) — “No human clinical trials exist yet... As of 2026, no registered Phase I or Phase II trials for KPV in humans are listed on ClinicalTrials.gov” (sha256 05ce38b81709c162)
5. [KPV Research & Evidence](https://peptidetreatments.com/peptides/kpv/research) — “KPV has zero human clinical trials. All proposed benefits for IBD, gut health... are extrapolated from cell culture and mouse studies” (sha256 b1a71cab0a117d12)
6. [Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin](https://pubmed.ncbi.nlm.nih.gov/28343991/) — “Lysine-proline-valine (KPV) is a C-terminal peptide fragment of α-melanocyte stimulating hormone with potent anti-inflammatory properties.” (sha256 034d8542b79e607e)
7. [KPV Peptide | Benefits, Safety & Buying Advice [2026]](https://www.innerbody.com/kpv-peptide) — “Of note, the research on KPV’s effects has been done primarily in animal models and human cell cultures, not in human subjects directly. Therefore, the support for its therapeutic uses is limited, albeit largely optimistic.” (sha256 f1b40935d2e73239)
8. [Inflammation-triggered self-immolative conjugates enable oral delivery of anti-inflammatory peptides](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802832/) — “Using three anti-inflammatory peptides (KPV, Ac-QAW, and IRW), we demonstrated that the engineered conjugates exhibit remarkable GI stability” (sha256 c63c58bb9e20015b)
9. [A Complete Guide for KPV](https://www.reddit.com/r/Ameano_Peptides/comments/1o7vx9t/a_complete_guide_for_kpv/) — “KPV (Lysine-Proline-Valine) is a small tripeptide derived from the C-terminal sequence of α-MSH (alpha-melanocyte stimulating hormone). It is known for its potent anti-inflammatory, immunomodulatory, and mucosal healing actions, particularly in gastrointestinal and epithelial tissues.” (sha256 f137279a72b6a3dd)
10. [The Best Peptide for Inflammation, Gut Health, and Visceral Fat Loss (KPV Peptide)](https://www.youtube.com/watch?v=wdCjXXmRoEw) — “KPV is a 3-amino-acid peptide (Lysine-Proline-Valine) that fights inflammation where it starts—inside your cells.” (sha256 9151569e2e688e48)
11. [Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists](https://pubmed.ncbi.nlm.nih.gov/22837805/) — “This study investigates the mechanism by which the α-melanocyte stimulating hormone-derived tripeptide, KPV, and the agonist of the dominant melanocortin receptor in airway epithelium (MC3R), γ-melanocyte stimulating hormone (γ-MSH), suppress inflammation in immortalised human bronchial airway epithelium.” (sha256 d4905e9f8fed4f5a)
12. [Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model](https://pubmed.ncbi.nlm.nih.gov/27458604/) — “The use of an anti-inflammatory tripeptide KPV (Lys-Pro-Val) transported by PepT1 was able to prevent carcinogenesis in WT mice.” (sha256 2c7e3a5552b9be23)
13. [Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis](https://pubmed.ncbi.nlm.nih.gov/28143741/) — “We found that HA-KPV-NPs exert combined effects against UC by both accelerating mucosal healing and alleviating inflammation.” (sha256 85ff7740a4df5f97)
14. [KPV tripeptide](https://en.wikipedia.org/wiki/KPV_tripeptide) — “KPV tripeptide (Lys-Pro-Val) is a tripeptide derivative that is derived from the C-terminal fragment of alpha-MSH. It has antiinflammatory effects, and is used in skincare products, as well as having been researched for other potential medical applications.” (sha256 36c577ba0ad55084)
15. [KPV Peptide: Benefits, Dosage & 2026 Legal Status](https://riteaid.com/peptides/kpv) — “It is one of the twelve peptides the FDA removed from the list that restricted compounding in April 2026, and one of seven under formal advisory review on July 23–24, 2026.” (sha256 db5dc4d42f519f94)
16. [KPV Peptide: Comprehensive Guide to Benefits, Dosage and ...](https://www.helimeds.com/blog/kpv-peptide) — “The FDAs Pharmacy Compounding Advisory Committee (PCAC) will review seven peptides to potentially allow compounders to produce them.” (sha256 1a84db2f15559700)
17. [Anyone here with experience using KPV or other peptides ...](https://www.reddit.com/r/Biohackers/comments/1q83047/anyone_here_with_experience_using_kpv_or_other/) — “I personally tried KPV subcutaneously. 200µg for 12 days (one 5mg vial). ... Significant improvements on the Bistrol scale. I no longer suffered from nighttime duodenal pain. My seborrheic dermatitis is greatly improving. More energy. No side effects.” (sha256 533adcc69aee62aa)
18. [KPV Peptide - Miracle Cure or Major Risk?](https://www.youtube.com/watch?v=5ph3S8mVuuE) — “Discover the science behind KPV peptide, a powerful tripeptide known for its anti-inflammatory and immune-balancing properties.” (sha256 757047d1739b0a63)
19. [KPV Peptide Side Effects](https://www.reddit.com/r/Longcovidgutdysbiosis/comments/1je6riv/kpv_peptide_side_effects/) — “Kpv & BPC157 both made me feel dizzy, impaired my sleep, gave me headaches and brain fog, and caused fatigue. It sucked bc I actually noticed ...” (sha256 27d6ddb2991b2ab0)
20. [KPV Peptide Side Effects](https://www.reddit.com/r/Longcovidgutdysbiosis/comments/1je6riv/kpv_peptide_side_effects/) — “Kvp simmers down the inflammation in MCAS.. almost instantly. 40 days in. 500 MCG daily. ... What I’ve noticed is since taking some peptides it’s taken the edge off and reduce the intensity of the instant reaction. Even that I’m deeply grateful for.” (sha256 354b8c5e7188d9cc)
21. [KPV peptides](https://www.reddit.com/r/Longcovidgutdysbiosis/comments/1iikbxd/kpv_peptides/) — “It definitely helped with gut repair but it took me a long time to titrate up my dose. It did cause paradoxical reactions early on. After months, I'm just now at 1 capsule every other day.” (sha256 2a4acde02fe8cca4)
22. [KPV peptides](https://www.reddit.com/r/Longcovidgutdysbiosis/comments/1iikbxd/kpv_peptides/) — “Start at a very low dose, you might herx. This has helped me a lot with my histamine tolerance.” (sha256 5f5349366a166398)
23. [Is anyone being helped by peptides?](https://www.reddit.com/r/MCAS/comments/1rpepqr/is_anyone_being_helped_by_peptides/) — “KPV & GHK-Cu (injections) have helped me immensely, both in terms of fatigue and in terms of food tolerance and related symptoms.” (sha256 ea9b580f85ff9b38)
24. [Is anyone being helped by peptides?](https://www.reddit.com/r/MCAS/comments/1rpepqr/is_anyone_being_helped_by_peptides/) — “KPV has helped me dramatically. About 80% reduction in symptoms.” (sha256 26215403736c8b18)
25. [KPV fatigue and apathy](https://www.reddit.com/r/Biohackers/comments/1ribbuz/kpv_fatigue_and_apathy/) — “Been on 200mcg of KPV for a few days and am a little fatigue but the apathy seems a bit strong.” (sha256 00f25373d416e5c9)
26. [This Peptide “Fixes” Your Gut... But There's a Catch](https://www.youtube.com/watch?v=spOpffLj9Oo) — “I have IBS, Crohn's and celiac. Carnivore, KPV and R e t a had helped me so much . I have my life back.” (sha256 d02234568b0e464f)
27. [How effective is KPV peptide? Is it really worth it?](https://www.reddit.com/r/Biohackers/comments/1s69j21/how_effective_is_kpv_peptide_is_it_really_worth_it/) — “Great for overall inflammation, skin inflammation and gut health , fungus , etc. My toe nail never gets yellow anymore, dandruff completely gone ...” (sha256 57951dafac775f7b)
28. [KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy](https://pubmed.ncbi.nlm.nih.gov/39252648/) — “Herein, an anti-inflammatory peptide (lysine-proline-valine peptides , KPV ) and the autophagy activator rapamycin (RAPA) are self-assembled to form new carrier-free spherical nanoparticles (NPs), which shows good stability and biosafety.” (sha256 9ae7a8a4af062f0d)
29. [Bioactive peptides and proteins for tissue repair](https://pmc.ncbi.nlm.nih.gov/articles/PMC11619216/) — “The KPV peptide from the bottom layer was rapidly released within 1 − 3 d to exert an anti-inflammatory effect during the early stages of wound healing, while ...” (sha256 0f19c82e79dc7bc5)
30. [Is KPV Peptide Safe To Take?](https://formationmed.com/is-kpv-peptide-safe-to-take/) — “KPV peptide can be safe to take when it is prescribed by a licensed medical provider and sourced from a licensed compounding pharmacy that ...” (sha256 1f4ebec2ddac30e8)
31. [KPV Peptide: Anti-Inflammatory Mechanisms and Research](https://newtropin.com/peptides/kpv) — “Research has identified receptor expression in intestinal, dermal, and central nervous system tissues, though the pharmacokinetic profile of KPV in humans remains to be fully characterized through clinical trials.” (sha256 d0b432513e6d634d)
32. [Best peptides and brands for MCAS ? BPC-157, KPV and ...](https://www.reddit.com/r/MCAS/comments/1lki5p2/best_peptides_and_brands_for_mcas_bpc157_kpv_and/) — “I have been using KPV Ultra and BPC-157 since April and no longer need to eat a low histamine diet.” (sha256 cd67690d781223ad)
33. [KPV Explained Simply (The Gut Inflammation Fighter)](https://www.reddit.com/r/PeptideProgress/comments/1u17ht6/kpv_explained_simply_the_gut_inflammation_fighter/) — “KPV is a specialized peptide for a specific problem: inflammation. If you have a clear inflammatory issue, especially gut or skin related ...” (sha256 b0ac0cc38b24588c)
34. [What is KPV and why is it being studied?](https://www.instagram.com/reel/DYfvjzVDjSD/) — “Benefits of KPV peptide therapy may include: • Support for gut barrier integrity • Reduced gastrointestinal inflammation • Improved digestive ...” (sha256 34717c876ab54320)
35. [Anti‐Inflammatory Peptides as Promising Therapeutics for Inflammatory Bowel Disease](https://onlinelibrary.wiley.com/doi/full/10.1002/jgh3.70212) — “The study conducted by Kucharzik and colleagues was a phase 2 clinical trial designed to investigate the efficacy of K(D)PT medication in UC cases.” (sha256 7bf9b69b81e9dfd0)
36. [KPV peptide guide](https://www.reddit.com/r/NTNPerformance/comments/1talx2b/kpv_peptide_guide/) — “KPV is a naturally occurring tripeptide. Three amino acids. Lysine, proline, valine. It's the C-terminal fragment of alpha-MSH which is a hormone your body already produces” (sha256 9f4f840ba2a05495)
37. [KPV: The Barrier Repair Peptide (Gut, Skin & Chronic Inflammation)](https://www.youtube.com/watch?v=XE0k4AW0uag) — “KPV is one of the smallest peptides studied in inflammation biology — but it may be one of the most important when it comes to gut health, skin barrier repair, immune balance, and chronic inflammation, especially in midlife.” (sha256 003a9d832bfc61cd)
38. [KPV: The Anti-Inflammatory Peptide Under FDA Review](https://healingmaps.com/kpv-peptide-anti-inflammatory-wound-healing/) — “Regulatory Update (April 2026): KPV is one of seven peptides scheduled for FDA Pharmacy Compounding Advisory Committee review on July 23, 2026.” (sha256 edce681d842064a2)
39. [KPV — Molecular Specifications & Research Monograph](https://peptidebiologix.com/kpv) — “The most significant clinical data comes from studies in inflammatory bowel disease patients. A pilot clinical trial investigated topical (intrarectal) administration of KPV in patients with mild to moderate ulcerative colitis.” (sha256 f5e2bff33ab55cff)
40. [Structural modification of the tripeptide KPV by reductive amination](https://pmc.ncbi.nlm.nih.gov/articles/PMC6023233/) — “The “parent” peptide , Ac- KPV -NH2 (12c) was degraded to its three constituent amino acids within 24 hours.” (sha256 080a04863bd88a9d)
41. [SS-31 and KPV peptides...what are your experiences?](https://www.reddit.com/r/MCAS/comments/1u92rpe/ss31_and_kpv_peptideswhat_are_your_experiences/) — “Anyone used SS-31 OR KPV? How did it help? What were you struggling with prior to starting? What MCAS symptoms did it help with? Did your fatigue improve?” (sha256 e4dbd26ff1ab91d2)
42. [Kpv peptide](https://www.reddit.com/r/Longcovidgutdysbiosis/comments/1agb1mz/kpv_peptide/) — “Apparently it can completely fix gut issues. It has immune system regulating properties and apparently can reverse MCAS.” (sha256 8a101178a03cdeb7)
43. [Massive worsening of symptoms after peptide usage?](https://www.reddit.com/r/MCAS/comments/1pd1ly4/massive_worsening_of_symptoms_after_peptide_usage/) — “I took 0.2 ml of BPC 157 on two consecutive days and 0.06 ml of KPV on the third day. An hour after the KPV injection, my problems started severely.” (sha256 db4fe795d43ec1e3)
44. [KPV Peptide and Ulcerative Colitis | Safe Gut Healing in Stamford CT](https://drsobo.com/blog/kpv-effectively-treats-ulcerative-colitis/) — “Clinical research supports KPV’s potential as a safe, targeted therapy for inflammatory bowel disease.” (sha256 bc31aa6c83923f3b)
45. [KPV Peptide](https://www.amiv.com/blog/detail/kpv-peptide) — “KPV is a powerful inflammation regulator. It blocks pro-inflammatory cytokines, such as TNF-alpha and IL-6, which are responsible for chronic inflammation.” (sha256 33a97830704ec99f)
46. [KPV Side Effects.](https://www.reddit.com/r/Biohackers/comments/1rfebe7/kpv_side_effects/) — “I started taking KPV subq 250 mcg once daily at night. I feel very fatigued and almost like a low grade common cold symptoms every day since I started. I’m on day 4.” (sha256 6bde73d181e2a32a)
47. [KPV peptides](https://www.reddit.com/r/MCAS/comments/1dp073i/kpv_peptides/) — “I have been taking it for two weeks and I swear it’s helping with heat (it’s been heat index of over 100 every day in north Texas) intolerance, skin rashes, bloating after eating, and anxiety. ... I used to really get short of breath often from random unknown triggers” (sha256 50f5c0df13e439ae)
48. [Symptoms almost completely gone.....peptides have turned everything around](https://www.reddit.com/r/LongCovid/comments/1pyyxem/symptoms_almost_completely_gonepeptides_have/) — “I started Retatrutide (GLP) months ago, then added KPV (MCAS/gut, etc) and GhK-Cu for inflammation. ... 2.5 months in and I'm almost back to my previous self. ... aches/pains, food reactions, GI issues, dizziness, memory issues, etc are 75-80% better” (sha256 fa639e92be143443)
49. [Therapeutic Peptides in Aesthetic, Metabolic and ...](https://www.mdpi.com/1422-0067/27/9/3890) — “KPV: A short anti-inflammatory peptide derived from Alpha-melanocyte-stimulating hormone (α-MSH). Research primarily in preclinical models links it to gastrointestinal tract protection, promotion of mucosal healing, and enhanced epithelial wound repair.” (sha256 0ce9105e5c2a6646)
50. [Inflammation-triggered self-immolative conjugates enable ...](https://www.science.org/doi/10.1126/sciadv.aea2989) — “Using three anti-inflammatory peptides (KPV, Ac-QAW, and IRW), we demonstrated that the engineered conjugates exhibit remarkable GI stability... In colitis mice, the KPV-based conjugate (proKPV) achieved a 3.8-fold greater colonic accumulation than free KPV, with enhanced efficacy even at a 20-fold lower dose.” (sha256 66a95153eca11928)
51. [Lysine-Proline-Valine peptide mitigates fine dust-induced ...](https://www.sciencedirect.com/science/article/abs/pii/S004081662500117X) — “KPV protects keratinocytes by mitigating PM10-induced pyroptosis and holds potential as a therapeutic agent for preventing environmental pollutant-related skin inflammation.” (sha256 2a9ee37c81a48f93)
52. [July 23-24, 2026: Meeting of the Pharmacy Compounding ...](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) — “On July 23, 2026, the Committee will discuss the following bulk drug substances... KPV-related bulk drug substances (KPV (free base)/ KPV acetate)... Wound healing and inflammatory conditions” (sha256 ec8a57bdb3a26fc0)
53. [5 Years Long Covid - Thymosin Alpha 1 Peptide - WOW!](https://www.reddit.com/r/covidlonghaulers/comments/1r5ekd8/5_years_long_covid_thymosin_alpha_1_peptide_wow/) — “After KPV peptide which made me feel good for like 48 hours. I am now testing Thymosin Alpha 1 Peptide... Conclusion: Effect seems to last 48-72 hours for TA-1 and 48 hours for KPV” (sha256 6453611d0d30512f)
54. [r/KPVPeptide](https://www.reddit.com/r/KPVPeptide/) — “I have been taking kpv for 8 days and was going great, I could feel my inflammation going down (no shoulder pain, no lower back pain, rosacea redness was way down) and then out of nowhere I started to get very little redness bumps... Could it be a herx reaction or an allergy?” (sha256 e3d7c490649f22ba)
55. [Peptide-based therapeutic and delivery strategies for inflammatory bowel disease](https://pmc.ncbi.nlm.nih.gov/articles/PMC12272339/) — “This review provides a comprehensive overview of the sources, structures, and mechanisms of therapeutic peptides for IBD management.” (sha256 1f41507c85a6d255)
56. [KPV Peptide | Healand Clinic](https://www.healand.co.uk/biohacking/kpv-peptide) — “KPV is the tripeptide Lys-Pro-Val, a short fragment derived from alpha-melanocyte-stimulating hormone. Research has focused on intestinal inflammation, epithelial transport and anti-inflammatory signalling in gut and skin models.” (sha256 d8a8aea4732aa0e1)
57. [Welcome to the KPV Peptide Community — Let’s Talk Inflammation, Recovery, and Real-Life Results](https://www.reddit.com/r/KPVPeptide/comments/1m7qu64/welcome_to_the_kpv_peptide_community_lets_talk/) — “I created this community because KPV deserves a deeper conversation. It’s one of the most underrated yet powerful peptides for inflammation, gut healing, injury recovery, skin flares, and even emotional regulation” (sha256 efd7ab6d9c866ff8)
58. [KPV Fixed my Acne Permanently](https://www.reddit.com/r/Biohackers/comments/1to8f07/kpv_fixed_my_acne_permanently/) — “After about a month or less I stopped getting any acne, and now maybe 3-4 months later I still had not gotten any acne... KPV healed my nutrient absorption, healed chronic acne and improved bio markers.” (sha256 08569877cc04bacf)
59. [KPV - Beverly Hills Rejuvenation Center](https://www.bhrcenter.com/peptides/kpv/) — “KPV is a naturally occurring tripeptide fragment of alpha-melanocyte stimulating hormone (α-MSH) that powerfully modulates inflammatory responses throughout the body. By targeting key inflammatory pathways, KPV supports tissue healing, reduces chronic inflammation, and promotes gut health through its unique anti-inflammatory and antimicrobial properties.” (sha256 679192216b420c30)
60. [Thoughts on KPV Peptide for Eczema?](https://www.reddit.com/r/eczema/comments/1sdsz9h/thoughts_on_kpv_peptide_for_eczema/) — “I think it works well on me. Been on it for about 4 or 5 weeks now and I dont get flare ups anymore. Noticed that when I stopped for 2 days, my upper lip began to itch” (sha256 ececf79fb4cb4541)
61. [KPV peptide takes Long Covid away](https://www.reddit.com/r/covidlonghaulers/comments/1qwmoc8/kpv_peptide_takes_long_covid_away/) — “Just want to update. KPV 500mcg~ subq peptide injection is taking my Long Covid symptoms away for 2 days. Unfortunately the long covid symptoms come back after 2 days.” (sha256 44c975d900bde306)
62. [X post on KPV for nausea](https://x.com/rahulmodifit/status/2069110309454061845) — “one of the most underrated uses of KPV might be helping with nausea from other peptides... within about 20 minutes the nausea was significantly better.” (sha256 dbf80d0f559ebb40)
63. [Peptides](https://www.reddit.com/r/lipedema/comments/1qydkg1/peptides/) — “I tried GHK but it stung too much and I tried both separately. Found for me KPV helps me. My skin has improved, not sure if it's helping my lipedema but my overall inflammation is down.” (sha256 87ed6ac55e8e8308)
64. [Long-term kpv peptide](https://www.reddit.com/r/MCAS/comments/1jc3ool/longterm_kpv_peptide/) — “is working incredibly well for me. Been taking it for about two weeks now. I have. It has made a world of difference.” (sha256 c96fd5b797e7bd1d)
65. [Anti‐Inflammatory Peptides as Promising Therapeutics Agent for Ulcerative Colitis and Crohn's Disease](https://pmc.ncbi.nlm.nih.gov/articles/PMC12206851/) — “This review evaluates anti‐inflammatory peptides (AIPs) as emerging therapeutic agents, focusing on their efficacy in Ulcerative Colitis and Crohn's disease. ... KPV Has Anti‐Inflammatory Potential in Murine ...” (sha256 9c3109248c8617f6)
66. [Recalibrating Retinal Immunity: Peptide-Based Strategies ...](https://biomedgrid.com/pdf/AJBSR.MS.ID.003638.pdf) — “Bioactive peptides like thymosin β4 and melanocortin-derived KPV exhibit immunomodulatory and neuroprotective effects by restoring epithelial integrity, reducing oxidative damage, and recalibrating local immune responses. ... the tripeptide KPV (Lys-Pro-Val), derived from α-MSH, attenuates retinal inflammation and preserves barrier function in diabetic retinopathy models by modulating IL-1β and tight junction protein expression [52].” (sha256 54e4a13dbe376a21)
67. [Recent Advances in KPV Peptide Delivery](https://www.scitechnol.com/peer-review/recent-advances-in-kpv-peptidedelivery-8OYD.php?article_id=18216) — “Current research updates in last decade for α-MSH analogue, Proline-Lysine-Valine (KPV) is provided in this review.” (sha256 a1ba6a6a9f5b545c)
68. [Does Kpv “reset” inflammation or is it working as long as ...](https://www.reddit.com/r/PeptidePathways/comments/1tt6uvy/does_kpv_reset_inflammation_or_is_it_working_as/) — “While treating other underlying causes For people who have used KPV for inflammation, did it feel like it helped your body calm things down and then stay better after stopping, or did the benefits only last while you were actively using it?” (sha256 792a061b397f81b5)
69. [KPV - what's your experience?](https://www.reddit.com/r/Peptidesource/comments/1qjdrwd/kpv_whats_your_experience/) — “Just added KPV to my stack (GLP3, GHKCU) after extensive review and I'm excited to see how this protocol turns out for my subject.” (sha256 e9e31f1f975c3bf7)
70. [Peptides will unleash the greatest consumer health wave ...](https://x.com/jefftangx/status/2030389563794042966) — “If implemented, this would re-legalize BPC-157, Thymosin Alpha-1, AOD-9604, Semax, Selank, KPV, and MOTS-c for compounding with a prescription.” (sha256 b173dbe3fb4327b7)
71. [Rapid Insights into KPV Peptide: A Brief Overview](https://www.reddit.com/r/healthwithjessicalana/comments/17y51gq/rapid_insights_into_kpv_peptide_a_brief_overview/) — “KPV peptide uses a transporter peptide called PepT1 to lower inflammation. PepT1 is responsible for absorbing small peptides from our diet, and ...” (sha256 dfa7744398c4ab01)
72. [KPV Peptide? Anyone had luck?](https://www.reddit.com/r/Longcovidgutdysbiosis/comments/1dq43y7/kpv_peptide_anyone_had_luck/) — “Just started this week. Will report back 🤓” (sha256 158a5d26f646aeb1)
73. [Forgotten Hair Loss Peptide by L'Oreal: KPV](https://www.reddit.com/r/HairlossResearch/comments/1evbxf6/forgotten_hair_loss_peptide_by_loreal_kpv/) — “KPV (Lysine-Proline-Valine) is a small peptide with potential benefits for hair health, especially in treating androgenetic alopecia.” (sha256 a08304e316aaa390)
74. [KPV peptide working well for mast cell and histamine symptoms](https://www.reddit.com/r/floxies/comments/148mgn6/kpv_peptide_working_well_for_mast_cell_and/) — “KPV peptide working well for mast cell and histamine symptoms. [MEDICATION]. Been having some good results with this injectable peptide ...” (sha256 75016a1813b9d96a)
75. [KPV peptide fixed my eczema](https://www.reddit.com/r/eczema/comments/1szorjy/kpv_peptide_fixed_my_eczema/) — “KPV peptide has healed my eczema in 2 weeks. It's not fda regulated but injecting kpv is the only thing that worked and gotten rid of my hand ...” (sha256 77386dbbd22d6dcb)
76. [Log - KPV - Autoimmune/Pain/Tendinitis](https://www.reddit.com/r/Hashimotos/comments/1pddx24/log_kpv_autoimmunepaintendinitis/) — “AI Summary KPV, similarity to LDN. Both KPV peptide and Low Dose Naltrexone (LDN) reduce inflammation by acting on the NF-κB pathway, ...” (sha256 2c26755cc5bc46fe)
77. [PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation](https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/) — “This study indicates that KPV is transported into cells by PepT1 and might be a new therapeutic agent for IBD.” (sha256 f33b4b74e7420d6a)
78. [Growth Factors-Loaded Temperature-Sensitive Hydrogel...](https://pubmed.ncbi.nlm.nih.gov/38289234/) — “... ( KPV tripeptide and epidermal growth factor). PHE-EK presented good thermosensitive properties...” (sha256 fce996d6ceb0a2df)
79. [The Benefits of Peptides: BPC157 & KPV for Healing and Gut Health](https://www.laserskinsolutions.com/blog/the-benefits-of-peptides-bpc157-kpv-for-healing-and-gut-health/) — “Studies have shown that KPV can reduce inflammation in intestinal cells, preserve the gut lining, and help restore balance in the microbiome.” (sha256 38a1485dd65ec6ca)
80. [What Does The KPV Peptide Do?](https://formationmed.com/what-does-the-kpv-peptide-do/) — “KPV is a tripeptide made up of three amino acids; lysine, proline, and valine derived from the hormone alpha-Melanocyte Stimulating Hormone (α-MSH).” (sha256 3470fd332045983c)
81. [BPC-157, KPV, Thymogen Alpha 1, Gut Feeling](https://www.reddit.com/user/LadyTeetles/comments/1eqtyrc/immune_health_and_healing_peptides_bpc157_kpv/) — “In this post, I will share information about using peptides for immune health , peptide properties, benefits, side effects, conditions that can ...” (sha256 59449ca42079c67f)
82. [Has anyone tried KPV for their inflammation?](https://www.reddit.com/r/endometriosis/comments/1stumj8/has_anyone_tried_kpv_for_their_inflammation/) — “Hi, I've recently been supplementing KPV sub q and it's helped a ton with the chaos of injuries and conditions I have. ... It made me realize that if I did end up relapsing in endo symptoms, I know my body would benefit from the kpv.” (sha256 7f131ab128be84d5)
83. [KPV peptide for SVT (not medical advice; personal experience)](https://www.reddit.com/r/SVTHeart/comments/1s6fv8g/kpv_peptide_for_svt_not_medical_advice_personal/) — “Interestingly, when I started taking KPV, for the full month of January and February 2026, I had ZERO SVT episodes… it got to a point where I was debating on cancelling my ablation... but I decided to continue to go forward with it still. As soon as I stopped taking it in preparation for my ablation (stopped KPV 2 weeks before), two days later had an episode. 2 weeks after my ablation, I was having a bunch of PVCs/PACs. ... and within days, no PVCs/PACs.” (sha256 8961a8400012fecb)
84. [GH peptides + KLOW blend saved my hair. before and after](https://www.reddit.com/r/tressless/comments/1rytxzu/gh_peptides_klow_blend_saved_my_hair_before_and/) — “GHK/KLOW (I normally do three months on KLOW then cycle off a month; but I run the GHK-Cu & KPV continuously, so I’m really just cycling off the BPC/TB4) definitely thickened my hair.” (sha256 d9c1724fa5ff43ef)
85. [The Future of Regenerative Healing: BPC-157, TB-500 ...](https://www.reddit.com/r/NewCellReplacement/comments/1n6hrz2/the_future_of_regenerative_healing_bpc157_tb500/) — “I take BPC, TB and KPV but not the copper. I am taking them for my sacro iliac region. They really help. Amazing stuff.” (sha256 35b246b50bd62028)
86. [Those who tried peptides - permanent shift in baseline?](https://www.reddit.com/r/covidlonghaulers/comments/1peun65/those_who_tried_peptides_permanent_shift_in/) — “Good to know that KPV seems a little more tolerable with a possible different set of side effects . I will report back on my KPV Ultra (spray) ...” (sha256 b396eb7d4402f100)
87. [KPV peptide description](https://x.com/humanupgradeai/status/2069088062441767130) — “KPV peptide is a three-amino-acid fragment that packs serious anti-inflammatory punch without the side effects of full alpha-MSH.” (sha256 1c43cc094fc544a2)
88. [KPV S tier claim](https://x.com/MrPept1de/status/2063810306820681817) — “I have real personal data from 15 real people ive helped and myself!! Im telling you. KPV is S tier!” (sha256 bedf97cd0f902b0b)
89. [Peptides - KPV](https://www.reddit.com/r/postvasectomypain/comments/1pl4twe/peptides_kpv/) — “I'm trialing KPV injections under careful clinical monitoring (blood markers) for Autoimmune issues. ... I do feel like the KPV is helping. ... Current protocol is: ... 5mg KPV inj subQ daily ... I plan to cycle off soon on KPV, will see how I do.” (sha256 72604b9be0ba6f3a)
90. [Reduce inflammation with KPV and BPC-157](https://www.reddit.com/r/lipedema/comments/1l850rf/reduce_inflammation_with_kpv_and_bpc157/) — “Hi everyone. I've been searching for peptides to manage inflammation lately. Has anyone tried KPV or BPC-157, ...” (sha256 c5ee4a70ead23708)
91. [KPV peptide post](https://x.com/SuppMasterX/status/2071649714915709405) — “🔥 KPV — IL PEPTIDE CHE NESSUNO TI RACCONTA Colon irritabile. Diverticoli. Intestino che brucia. Esiste un peptide da tre lettere che nei modelli animali di colite spegne l’infiammazione meglio del cortisone.” (sha256 88d8cc770c6b552d)
92. [KPV in stack](https://x.com/Breedlove22/status/2071613118762127506) — “(3/4) KPV A tiny peptide that comes from one of your own calming hormones, and it goes straight at inflammation in the gut. It was the steady workhorse of the stack, well tolerated with nothing to manage.” (sha256 788b970908a1af6b)
93. [KPV recommendation](https://x.com/HuntersGrundle/status/2071648239783223621) — “Seriously take a look into KPV (a peptide). I personally know half a dozen people that it's helped tremendously with for gut and bowel health issues (chrons/ibs/etc).” (sha256 2452aa619a79368b)
94. [KPV: Comprehensive Guide](https://www.reddit.com/r/APRHealthSolutions/comments/1q3bc3r/kpv_comprehensive_guide/) — “What Is KPV? KPV is a tripeptide fragment (Lysine–Proline–Valine) derived from the α-MSH (alpha-melanocyte-stimulating hormone) sequence.” (sha256 7ca222782d62246a)
95. [r/OptimumFormulaReviews – KPV (10mg) Guide](https://www.reddit.com/r/OptimumFormulaReviews/comments/1qhge85/roptimumformulareviews_kpv_10mg_guide/) — “KPV is a tripeptide fragment (Lys-Pro-Val ) derived from α-MSH. Researchers study it for gut barrier support, immune modulation, ...” (sha256 09ce439e2280bd30)
96. [The Tripeptide Targeting Gut Inflammation and Skin Repair](https://www.reddit.com/r/IonPeptideGuide/comments/1rztvf6/kpv_quick_guide_the_tripeptide_targeting_gut/) — “KPV (Lysine-Proline-Valine ) is a naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (α-MSH).” (sha256 e6de02f4d090a7b6)
97. [X post on KPV science](https://x.com/alextatem/status/2051439184452178178) — “We cover the real science behind KPV , including its origin from alpha-MSH, its unique anti-inflammatory mechanisms (NF-kB & MAPK inhibition), ...” (sha256 9edb7f2d273a32dd)
98. [X post on KPV FDA and personal use](https://x.com/alexaaronlab/status/2063272321243103549) — “KPV is one of the most underrated peptides on the FDA's July review list. KPV is among the few peptides that I keep in my stack year-round.” (sha256 f7e97fb48b726d5d)
99. [X post preferring KPV](https://x.com/johnpaulp/status/2067238212502782185) — “KPV is by far my favorite - I would take KPV over BPC-157 and TB-500 any day.” (sha256 c5edf2c66ab7aa09)
100. [Has anyone tried or used KPV peptides for help with HS?](https://www.reddit.com/r/Hidradenitis/comments/1pqlj24/has_anyone_tried_or_used_kpv_peptides_for_help/) — “I take bpc157, tb500 and Kpv with glutathione. It works so good. Within 2 weeks te spots are almost gone and the ugly skin gets better also.” (sha256 f3a545670cc3915f)
101. [KPV peptide](https://www.reddit.com/r/CIRS/comments/1q9ff17/kpv_peptide/) — “Oral didn’t work for me but injections worked very well! My MSH went from less than 1 to 28 in a few months.” (sha256 c65d210327a4d4b7)
102. [KPV Is More Than Just Anti-Inflammation](https://www.reddit.com/r/BodyOptimization/comments/1r9ej1f/kpv_is_more_than_just_antiinflammation/) — “When most people hear KPV, they think “anti-inflammatory peptide” and stop there. And yes, it's very good at calming chronic systemic inflammation.” (sha256 9ea18d20b3dfec52)
103. [Peptides for RA while on prescribed immune modulator?](https://www.reddit.com/r/rheumatoid/comments/1rb5enm/peptides_for_ra_while_on_prescribed_immune/) — “I use KPV daily for anti-inflammatory benefits . I also use thymosin alpha 1 for its immune modulation. These are in addition to HCQ and LDN.” (sha256 0c8f44d5d812d21d)
104. [FDA Evaluation of KPV-Related Bulk Drug Substances (KPV free base and KPV acetate) for Inclusion on the 503A Bulk Drug Substances List — PCAC briefing document, 12 May 2026](https://www.fda.gov/media/193346/download) — “There is a lack of evidence to evaluate the effectiveness of KPV (free base) and KPV acetate products for the nominated uses of wound healing and inflammatory conditions. The nomination did not include, and FDA did not find any information on the use of KPV (free base) or KPV acetate administered in humans.” (sha256 c154186ac25f763c)
105. [July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee — FDA](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) — “On July 23, 2026, the Committee will discuss the following bulk drug substances being considered for inclusion on the 503A Bulks List: BPC-157-related bulk drug substances, KPV-related bulk drug substances (KPV (free base)/ KPV acetate), TB-500-related bulk drug substances, and MOTs-C-related bulk drug substances. Uses evaluated for KPV: Wound healing and inflammatory conditions.” (sha256 f8b4d27c3afa7104)
106. [FDA Briefing Document Introduction, Pharmacy Compounding Advisory Committee, July 23-24 2026 — Points to Consider](https://www.fda.gov/media/193342/download) — “3. FDA is proposing that KPV (free base) NOT be included on the 503A Bulks List. 4. FDA is proposing that KPV acetate NOT be included on the 503A Bulks List.” (sha256 9e44c06ba4257724)
107. [Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — FDA](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) — “KPV — FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration. FDA lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans.” (sha256 f546258375f374ba)
108. [Pharmacy Compounding Advisory Committee; Notice of Meeting — Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List, 91 FR (16 April 2026)](https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request) — “KPV (free base), KPV acetate — Uses evaluated: Wound healing and inflammatory conditions.” (sha256 a413040e7eb7961a)
109. [Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008 (PMID 18061177)](https://pubmed.ncbi.nlm.nih.gov/18061177/) — “Nanomolar concentrations of KPV inhibit the activation of NF-kappaB and MAP kinase inflammatory signaling pathways, and reduce pro-inflammatory cytokine secretion. We found that KPV acts via PepT1 expressed in immune and intestinal epithelial cells. hPepT1 had a low Km of ~160 microM for KPV.” (sha256 4a3f12dc1f424864)
110. [Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008 (PMID 18092346)](https://pubmed.ncbi.nlm.nih.gov/18092346/) — “In MC1Re/e mice, KPV treatment rescued all animals in the treatment group from death during DSS colitis. These effects seem to be at least partially independent of MC1R signaling.” (sha256 16156103ea30f216)
111. [Brzoska T, et al. Terminal signal: anti-inflammatory effects of alpha-MSH related peptides beyond the pharmacophore. Adv Exp Med Biol 2010 (PMID 21222263)](https://pubmed.ncbi.nlm.nih.gov/21222263/) — “KPV, C-terminal tripeptide of alpha-MSH, which lacks the entire sequence motif required for binding to any of the known MC-Rs, retains almost all of the anti-inflammatory capacity of the full hormone, but in its activities display a lack of any pigmentary action. While the exact signaling mechanism utilized by KPV and related peptides currently is unknown...” (sha256 14742d54f70d2200)
112. [Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides. Endocr Rev 2008 (PMID 18612139)](https://pubmed.ncbi.nlm.nih.gov/18612139/) — “One obstacle limiting the use of alpha-MSH in inflammatory disorders is its pigmentary effect. Due to its preserved antiinflammatory effect but lack of pigmentary action, the C-terminal tripeptide of alpha-MSH, KPV, has been delineated as an alternative for antiinflammatory therapy.” (sha256 6c2029a66c683e87)
113. [Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action. Int J Physiol Pathophysiol Pharmacol 2012 (PMID 22837805)](https://pubmed.ncbi.nlm.nih.gov/22837805/) — “The KPV effect was associated with its nuclear import, IkappaBalpha stabilisation and suppressed nuclear translocation of YFP-tagged p65RelA. Competition assays revealed an interaction between KPV and the Imp-alpha3 binding site on p65RelA.” (sha256 5cd86d2c1dddffb6)
114. [Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol 2000 (PMID 10670585)](https://pubmed.ncbi.nlm.nih.gov/10670585/) — “alpha-MSH and its carboxy-terminal tripeptide (11-13, KPV) were determined to have antimicrobial influences against two major and representative pathogens: Staphylococcus aureus and Candida albicans. Antimicrobial effects occurred over a broad range of concentrations including the physiological (picomolar) range.” (sha256 b57fc7fcb341d449)
115. [Grieco P, et al. Three-dimensional structure of the alpha-MSH-derived candidacidal peptide [Ac-CKPV]2. J Pept Res 2005 (PMID 15946192)](https://pubmed.ncbi.nlm.nih.gov/15946192/) — “By inserting a Cys-Cys linker between two units of KPV, we designed the dimer [Ac-CKPV]2 that showed excellent candidacidal effects in pilot tests. [Ac-CKPV]2 was active against azole-resistant Candida spp.” (sha256 72024e4ffdcbaaa2)
116. [Bonfiglio V, et al. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res 2006 (PMID 16965771)](https://pubmed.ncbi.nlm.nih.gov/16965771/) — “Rabbits were topically treated with KPV 1, 5 or 10 mg/ml (30 microl), two drops four times in a day, for 4 days. Sixty hours later, eight out of eight (100%) corneas treated with KPV or SP were completely re-epithelialized.” (sha256 535637382aadfc08)
117. [Pawar S, Banga AK. Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates. Biomed Chromatogr 2015 (PMID 25298219)](https://pubmed.ncbi.nlm.nih.gov/25298219/) — “Under stress conditions (acid, alkali and hydrogen peroxide) KPV yielded lys-pro-diketopiperazine as major degradation product, which was identified by flow injection MS analysis. The LOD and LOQ of KPV were 0.01 and 0.25 microg/mL.” (sha256 d59301603d687d7b)
118. [Pawar S, Toti U, Kaushik R, Banga AK. Transdermal iontophoretic delivery of lysine-proline-valine (KPV) peptide across microporated human skin. J Pharm Sci 2017 (PMID 28343991)](https://pubmed.ncbi.nlm.nih.gov/28343991/) — “KPV permeation was less than detectable levels (limit of detection, 0.01 microg/mL) by simple passive diffusion. However, KPV permeation was increased to 4.4 microg/cm2/h by MN treatment. ITP and ITP + MN increased the permeation rate by 8 and 35 fold, respectively, as compared to MN alone.” (sha256 31ad093998262ecc)
119. [Laroui H, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 2010 (PMID 19909746)](https://pubmed.ncbi.nlm.nih.gov/19909746/) — “By using NPs, KPV can be delivered at a concentration that is 12,000-fold lower than that of KPV in free solution, but with similar therapeutic efficacy.” (sha256 6bfea01472491597)
120. [Xiao B, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther 2017 (PMID 28143741)](https://pubmed.ncbi.nlm.nih.gov/28143741/) — “Oral administration of HA-KPV-NPs encapsulated in a hydrogel (chitosan/alginate) exhibited a much stronger capacity to prevent mucosa damage and downregulate TNF-alpha, thus they showed a much better therapeutic efficacy against UC in a mouse model.” (sha256 4699bf9df331e341)
121. [Viennois E, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol 2016 (PMID 27458604)](https://pubmed.ncbi.nlm.nih.gov/27458604/) — “The use of an anti-inflammatory tripeptide KPV (Lys-Pro-Val) transported by PepT1 was able to prevent carcinogenesis in WT mice. When administered to PepT1-KO mice, KPV did not trigger any of the inhibitory effect on tumorigenesis observed in WT mice.” (sha256 a550d8dc757bddaf)
122. [Self-cross-linked hydrogel of cysteamine-grafted gamma-polyglutamic acid stabilized tripeptide KPV for alleviating TNBS-induced ulcerative colitis in rats. ACS Biomater Sci Eng 2021 (PMID 34547895)](https://pubmed.ncbi.nlm.nih.gov/34547895/) — “KPV solution is very unstable when rectally administered, compromising its therapeutic efficacy. The stability of KPV in the SH-PGA hydrogel was obviously enhanced, which was presented by detecting its anti-inflammatory activity and promoting cell migration potential after 2 h of exposure to 37 degrees C.” (sha256 82a6479db5feabf1)
123. [In situ mucoadhesive hydrogel carrying tripeptide KPV for chemotherapy-induced oral mucositis. Biomater Sci 2021 (PMID 34846053)](https://pubmed.ncbi.nlm.nih.gov/34846053/) — “KPV@PPP_2%E exhibited strong antibacterial efficacy against S. aureus. KPV@PPP_2%E hydrogel also had an anti-bacterial effect on MRSA-infected gingival ulcer wounds.” (sha256 d8ab409449ee6929)
124. [Skin-adaptive film dressing with smart-release of growth factors accelerated diabetic wound healing. Int J Biol Macromol 2022 (PMID 36240893)](https://pubmed.ncbi.nlm.nih.gov/36240893/) — “An anti-inflammatory tripeptide (KPV) and epidermal growth factor (EGF) as biologic factors were respectively encapsulated in the bottom layer and the middle-top two layers of AGB film. KPV was firstly released within 3 day. K-E-AGB could significantly improve the repair rate of full-thickness skin wound on diabetic mice.” (sha256 6cf5ca9e44111106)
125. [Inflammation-triggered self-immolative conjugates enable oral delivery of anti-inflammatory peptides. Sci Adv 2026 (PMC12802832)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802832/) — “In colitis mice, the KPV-based conjugate (proKPV) achieved a 3.8-fold greater colonic accumulation than free KPV, with enhanced efficacy even at a 20-fold lower dose. Oral administration of proKPV at 0.5 and 2.5 mg/kg for 7 consecutive days provided robust protection. By contrast, free KPV at 1 mg/kg showed no beneficial effects.” (sha256 a8f4f35f33054914)
126. [Structural modification of the tripeptide KPV by reductive glycoalkylation of the lysine residue. PLoS One 2018 (PMID 29953505)](https://pubmed.ncbi.nlm.nih.gov/29953505/) — “Antimicrobial assays, under a variety of conditions, showed no activity for Ac-KPV-NH2 or the alpha- or epsilon-glycoalkylated analogs. Glycoalkylated peptides did, however, show stability toward proteolytic enzymes.” (sha256 51b495554b255762)
127. [Hedley SJ, et al. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol 2004 (PMID 15102092)](https://pubmed.ncbi.nlm.nih.gov/15102092/) — “No elevation in cyclic AMP was detected in either HaCaT or normal human keratinocytes in response to alpha-MSH, KPV or ACTH peptides.” (sha256 f560a484ea32e66c)
128. [Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J 1989 (PMID 2550304)](https://pubmed.ncbi.nlm.nih.gov/2550304/) — “Alpha-MSH [11-13] inhibited swelling in a dose-related fashion. The effects of graded doses of alpha-MSH [11-13] on ear swelling induced by picryl chloride in mice were compared with the effects of saline and a large dose of corticosteroid.” (sha256 3e74528ebacae3dc)
129. [Lysine-proline-valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kB pathway. Tissue Cell 2025 (PMID 40073467)](https://pubmed.ncbi.nlm.nih.gov/40073467/) — “Treatment with 50 microg/mL of KPV restored cell viability and reduced IL-1beta secretion disrupted by PM10 exposure. In a three-dimensional (3D) skin model, KPV treatment effectively attenuated the inflammatory cell death induced by PM10.” (sha256 8b0b0dc3d8e6c2d5)
130. [Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARgamma pathway in HepG2 cells. Cytotechnology 2026 (PMID 42064835)](https://pubmed.ncbi.nlm.nih.gov/42064835/) — “Treatment with KPV (100 microg/mL) significantly attenuated OA-induced lipid accumulation and suppressed FAS expression without inducing cytotoxicity.” (sha256 95a4b193e0af4572)
131. [KPV and RAPA self-assembled into carrier-free nanodrugs for vascular calcification therapy. Adv Healthc Mater 2024 (PMID 39252648)](https://pubmed.ncbi.nlm.nih.gov/39252648/) — “In vivo and in vitro, KPV-RAPA NPs significantly inhibit VC in mice compared to the other treatment groups. Mechanistically, KPV-RAPA NPs inhibit inflammatory responses and activated autophagy.” (sha256 12b91d16af42e050)
132. [ClinicalTrials.gov API v2 query for KPV peptide, run 4 August 2026](https://clinicaltrials.gov/api/v2/studies?query.term=KPV+peptide&countTotal=true) — “{"totalCount": 0}” (sha256 16dae4b5d01d22f3)
133. [PubChem CID 125672 — Lys-Pro-Val](https://pubchem.ncbi.nlm.nih.gov/compound/125672) — “MolecularFormula C16H30N4O4; MolecularWeight 342.43; IUPACName (2S)-2-[[(2S)-1-[(2S)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoic acid” (sha256 9ef56b0a9d9007d2)